Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia

Schizophrenia Research

Volumn 58, Issue 1, 2002, Pages 69-74

  Shirayama, Yukihiko ^a,d   Hashimoto, Kenji ^c   Suzuki, Yoshio ^b   Higuchi, Teruhiko ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b Kanto Teishin Hospital   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACTH; Cortisol; Negative symptoms; Progesterone; Schizophrenia; Testosterone

Indexed keywords

BIPERIDEN; CHLORPROMAZINE; CORTICOTROPIN; DIAZEPAM; ETIZOLAM; FLUPHENAZINE; HALOPERIDOL; HYDROCORTISONE; NITRAZEPAM; PERPHENAZINE; PRASTERONE SULFATE; PROGESTERONE; TESTOSTERONE; THIORIDAZINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MEASUREMENT; NEGATIVE SYNDROME; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RADIOIMMUNOASSAY; RATING SCALE; SCHIZOPHRENIA; TESTOSTERONE BLOOD LEVEL;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; DEHYDROEPIANDROSTERONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROGESTERONE; PSYCHIATRIC STATUS RATING SCALES; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STEROIDS; TESTOSTERONE;

EID: 0036842387     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00367-X     Document Type: Article

References (29)

1. Andreasen N.C. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry. 139:1982;784-788.
2. Breier A., Buchanan R.W. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sci. 51:1992;1527-1534.
3. Breier A., Wolkowitz O.M., Doran A.R., Bellar S., Picker D. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Res. 25:1988;187-194.
4. Deis R.P., Leguizamon E., Jahn G.A. Feedback regulation by progesterone of stress-induced prolactin release in rats. J. Endocrinol. 120:1989;37-43.
5. Del Rio G., Velardo A., Menozzi R., Zizzo G., Tavernari V., Venneri M.G., Marrama P., Petraglia F. Acute estradiol and progesterone administration reduced cardiovascular and catecholamine responses to mental stress in menopausal women. Neuroendocrinology. 67:1998;269-274.
6. Dewan M.J., Pandurangi A.H., Levy B.F., Boucher M.L., Major L.F. Are schizophrenics with abnormal dexamethasone suppression test results a distinct subgroup? Acta Psychiatr. Scand. 72:1985;274-277.
7. Foster P. Neuroleptic equivalence. J. Pharmacol. 243:1989;431-432.
8. Freeman E.W., Purdy R.H., Coutifaris C., Rickels K., Paul S.M. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 58:1993;478-484.
9. Herz M., Fava G.A., Molnar G., Edwards L. The dexamethasone suppression test in newly hospitalized schizophrenic patients. Am. J. Psychiatry. 142:1985;127-129.
10. Kudoh A., Kudo T., Ishihara H., Matsuki A. Depressed pituitary-adrenal response to surgical stress in chronic schizophrenic patients. Neuropsychobiology. 36:1997;112-116.
11. Lerer B., Ran A., Blacker M., Silver H., Weller M., Drummer D., Ebstein B., Caleu A. Neuroendocrine responses in chronic schizophrenia. Schizophr. Res. 1:1988;405-410.
12. Marx C.E., Lieberman J.A. Psychoneuroendocrinology of schizophrenia. Psychiatr. Clin. North Am. 21:1998;413-434.
13. Meltzer H.Y., Lee M.A., Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology. 24:2001;278-290.
14. Mokrani M.C., Duval F., Crocq M.A., Bailey P.E., Macher J.P. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology. 20:1995;365-375.
15. Muck-Seler D., Pivac N., Jakovljevic M., Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone supression test in schizophrenic patients. Biol. Psychiatry. 45:1999;1433-1439.
16. Munro J.G., Hardiker T.M., Leonard D.P. The dexamethasone suppression test in residual schizophrenia with depression. Am. J. Psychiatry. 141:1984;250-252.
17. Newcomer J.W., Faustman W.O., Whiteford H.A., Moses J.A. Jr., Csernansky J.G. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol. Psychiatry. 29:1991;855-864.
18. Purdy R.H., Morrow A.L., Moore P.H. Jr. Stress-induced elevation of γ-aminobutyric acid type A receptor-active steroids in rat brain. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4553-4557.
19. Räsänen P., Hakko H., Visuri S., Paanila J., Kapanen P., Suomela T., Tiihonen J. Serum testosterone levels, mental disorders and criminal behaviour. Acta Psychiatr. Scand. 99:1999;348-352.
20. Rinieris P., Hatzimanolis J., Markianon M., Stefanis C. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology. 22:1989;146-149.
21. Rubinow D.R., Schmidt P.J. Androgens, brain, and behavior. Am. J. Psychiatry. 153:1996;974-984.
22. Schultz S.K., Andreasen N.C. Schizophrenia. Lancet. 353:1999;1425-1430.
23. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry. 155:1998;1310-1318.
24. Tandon R., Mazzara C., DeQuardo J., Craig K.A., Meador-Woodruff J.H., Goldman R. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol. Psychiatry. 29:1991;953-964.
25. Tsuchiya T., Horii I. Differential effects of acute and chronic immobilization stress on plasma testosterone levels in male syrian hamsters. Psychoneuroendocrinology. 20:1995;95-102.
26. Viau V., Meaney M.J. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J. Neurosci. 16:1996;1866-1876.
27. Walder D.J., Walker E.F., Lewine R.J. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry. 48:2000;1121-1132.
28. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 104:1997;667-685.
29. Yates W.R. Testosterone in Psychiatry - risks and benefits. Arch. Gen. Psychiatry. 57:2000;155-156.